On May 4, 2021 VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients’ cytotoxic T-cells targeting a wide range of cancer-related antigens, reported that the Company will participate in several scientific and industry events this month (Press release, Vaximm, MAY 4, 2021, View Source [SID1234579171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Heinz Lubenau, Chief Executive Officer of VAXIMM, and the management team will attend the following conferences:

18th CIMT (Free CIMT Whitepaper) Annual Meeting
May 10-12, 2021, Virtual Event
– To schedule a meeting with the Company, please contact [email protected].

21st Bio€quity Europe
May 17-19, 2021, Virtual Event
– Company presentation.
– To request a meeting, please sign up through the event’s partneringONE meeting system.

SACHS FORUM: 7th Annual Immuno-Oncology Innovation Forum
May 18-20, 2021, Virtual Event
– Company presentation.
– Panel discussion "Latest Advances in Cell & Gene Therapies.", 6:50 pm CEST, 19 May.
– To schedule a meeting, please sign up in the event’s online meeting system.

17th Annual Anglonordic Life Science Conference
May 25-26, 2021, Virtual Event
– Company presentation during session, "Biotech Investment and Technology Investment," 12 pm CEST, 26 May.
– To schedule a meeting, please sign up in the online meeting system.

For updates, please see the Events section of the Company’s website.